gefitinib

You have access
EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
GIUSEPPINA IMPROTA, GIULIA VITA, ALFREDO TARTARONE, GIOVANNI CALICE, LUDMILA CARMEN OMER and ANGELA ZUPA

Anticancer Research January 2025, 45 (1) 335-340; DOI: https://doi.org/10.21873/anticanres.17421
You have access
Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis
FRANCISCO CEZAR AQUINO DE MORAES, MARIA EDUARDA CAVALCANTI SOUZA, EMANUELE ROCHA DA SILVA, MICHELE KREUZ and ROMMEL MARIO RODRIGUEZ BURBANO

Anticancer Research December 2024, 44 (12) 5361-5370; DOI: https://doi.org/10.21873/anticanres.17363
You have access
Interactive Analysis of UTX-114 Family With EGFR-tyk: Molecular Features of Acetyl Glycosylated Gefitinib
KAZUTO OHKURA, ATSUSHI TABATA and YOSHIHIRO UTO

Anticancer Research August 2024, 44 (8) 3587-3591; DOI: https://doi.org/10.21873/anticanres.17181
You have access
Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells
BYUNG CHUL JUNG, SUNG-HUN WOO, SUNG HOON KIM and YOON SUK KIM

Anticancer Research May 2024, 44 (5) 1853-1862; DOI: https://doi.org/10.21873/anticanres.16987
You have access
Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression
LENA HUBER, RICHARD BIRK, MANUEL KNUETTEL, NICOLE ROTTER, CHRISTOPH ADERHOLD, CLAUDIA SCHERL, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research July 2022, 42 (7) 3403-3411; DOI: https://doi.org/10.21873/anticanres.15827
You have access
Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
MARTIN SVATON, MONIKA BRATOVA, ONDREJ FISCHER, JANA KREJCI, LEONA KOUBKOVA, MARKETA CERNOVSKA, MICHAL HRNCIARIK, MILADA ZEMANOVA, HELENA COUPKOVA, BEDRICH PORZER, DANIEL DOLEZAL, TANA TUZOVA, KAROLINA HURDALKOVA, MAGDA BARINOVA and JANA SKRICKOVA

Anticancer Research April 2021, 41 (4) 2059-2065; DOI: https://doi.org/10.21873/anticanres.14975
You have access
Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC
RICHARD BIRK, ANGELA SCHELL, CHRISTOPH ADERHOLD, STEPHAN HOCH, LENA HUBER, CORNELIA EMIKA MUELLER, ANNE LAMMERT, CLAUDIA SCHERL, NICOLE ROTTER, J. ULRICH SOMMER and BENEDIKT KRAMER

Anticancer Research November 2020, 40 (11) 6195-6203; DOI: https://doi.org/10.21873/anticanres.14639
You have access
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma
BENDIKT KRAMER, ANGELA SCHELL, CHRISTOPH ADERHOLD, LENA HUBER, C. EMIKA MUELLER, NICOLE ROTTER and RICHARD BIRK

Anticancer Research July 2020, 40 (7) 3847-3855; DOI: https://doi.org/10.21873/anticanres.14374
You have access
Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status
LENA HUBER, RICHARD BIRK, NICOLE ROTTER, CHRISTOPH ADERHOLD, ANNE LAMMERT, FREDERIC JUNGBAUER and BENEDIKT KRAMER

Anticancer Research February 2020, 40 (2) 825-835; DOI: https://doi.org/10.21873/anticanres.14014
You have access
Tetrandrine Increases the Sensitivity of Human Lung Adenocarcinoma PC14 Cells to Gefitinib by Lysosomal Inhibition
EIKO SATO, SINYA OHTA, KENJIRO KAWAKAMI, MANA IKEDA, TATSUO TAKAHASHI, SHINJIRO KOBAYASHI and MASAAKI NOMURA

Anticancer Research December 2019, 39 (12) 6585-6593; DOI: https://doi.org/10.21873/anticanres.13874

Main menu

User menu

Search

gefitinib

Pages